EUCTR2007-006453-12-IT进行中（未招募）1 期
A multi-centre, multinational, open-label study to evaluate the long-term safety, tolerability and efficacy of NS-304 in the treatment of pulmonary arterial hypertension in subjects aged 18 years and over (open extension study to NS 304/-02) - ND
IPPON SHINYAKU CO., LTD.0 个研究点目标入组 39 人开始时间: 2008年7月21日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The main criteria for inclusion are subjects who have completed the NS 304/-02 study and have signed informed consent for participation in this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Subjects with medically abnormal findings (ECG, physical examination, AEs) at the end of Visit 7 (Week 17) of the preceding double-blind study that the Investigator considers not appropriate to enter this study.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate if selexipag is safe and efficacious for the treatment of pulmonary arterial hypertensioPulmonary arterial hypertension (PAH) (idiopathic PAH, familial PAH, and PAH associated with collagen disease, corrected congenital vitium or anorexigen useMedDRA version: 19.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2007-006453-12-ATActelion Pharmaceuticals Ltd.40
进行中（未招募）
1 期
Study to evaluate if selexipag is safe and efficacious for the treatment of pulmonary arterial hypertensiopulmonary arterial hypertension (PAH) (idiopathic PAH, familial PAH, and PAH associated with collagen disease, corrected congenital vitium or anorexigen useMedDRA version: 18.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2007-006453-12-BEActelion Pharmaceuticals Ltd40
进行中（未招募）
1 期
An open label, multinational, multicenter study to evaluate the safety of HX575 recombinant human erythropoietin alfaEUCTR2008-004340-37-SKHexal Biotech ForschungsGmbH800
进行中（未招募）
不适用
An open label, multinational, multicenter study to evaluate the safety of HX575 recombinant human erythropoietin alfaEUCTR2008-004340-37-DEHexal AG800
进行中（未招募）
1 期
An open label, multinational, multicenter study to evaluate the safety of HX575 recombinant human erythropoietin alfaEstudio abierto, multicéntrico y multinacional para evaluar la seguridad de la eritropoyetina humana recombinante alfa HX575Subjects with chronic kidney disease (CKD) previously enrolled in other efficacy and/or safety studies with HX575, after these subjects have participated in the earlier study.Pacientes con enfermedad renal crónica previamente incluídos en otros ensayos de eficacia y/o seguridad con HX575, tras su participación en el estudio anterior.MedDRA version: 9.1Level: LLTClassification code 10009120Term: Chronic renal failure anaemiaEUCTR2008-004340-37-ESHexal AG